Abstract
High cure rates are now achieved for children diag-
nosed with Burkitt lymphoma (BL) in the western world, however
outcome for children who do not respond to therapy remains dire.
Moreover, only 48% of children are cured by front-line therapies in
resource-constrained countries such as Malawi. Although there is a
clear need to understand the underlying biology of these hard-to-
treat BLs, material is often limited and the required amount of DNA
for genomic analysis is often not attainable. It is therefore important
to identify methods to ensure we can analyse the genomes of these
patients
nosed with Burkitt lymphoma (BL) in the western world, however
outcome for children who do not respond to therapy remains dire.
Moreover, only 48% of children are cured by front-line therapies in
resource-constrained countries such as Malawi. Although there is a
clear need to understand the underlying biology of these hard-to-
treat BLs, material is often limited and the required amount of DNA
for genomic analysis is often not attainable. It is therefore important
to identify methods to ensure we can analyse the genomes of these
patients
| Original language | English |
|---|---|
| Pages (from-to) | 62-62 |
| Journal | British Journal of Haematology |
| DOIs | |
| Publication status | Published - 4 Oct 2015 |
| Event | Fifth International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin Lymphoma - Varase, Italy Duration: 22 Oct 2015 → 24 Oct 2015 https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13753 |